# A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

> **NCT05229562** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 84 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** BIIB122

## Key facts

- **NCT ID:** NCT05229562
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-17
- **Primary completion:** 2022-09-07
- **Final completion:** 2022-09-07
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05229562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05229562, "A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05229562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*